Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 7/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411295 | 0.82 | MAPK14 (0.41) | NPY5RBTKRAB9AKDM4ELDHA | |
| SCHEMBL6403222 | 0.74 | GRK6 (0.35) | RAB9ACETPKDM4ELMNAHPGD | |
| SCHEMBL16907285 | 0.74 | BTK (0.49) | NPY5RBTKRAB9AKDM4ELDHA | |
| SCHEMBL6406665 | 0.72 | NPY5R (0.42) | NPY5RBTKRAB9AKDM4ELDHA | |
| SCHEMBL6405361 | 0.71 | ALDH1A1 (0.56) | RAB9AKDM4ELMNAHPGD | |
| SCHEMBL13831663 | 0.69 | HPGD (0.42) | RAB9AKDM4EEPHX2LMNAHPGD | |
| SCHEMBL6408678 | 0.69 | CYP3A4 (0.40) | NPY5RBTKKDM4ELDHAEPHX2 | |
| SCHEMBL6408310 | 0.69 | KMT2A (0.52) | RAB9AKDM4ELMNAHPGD | |
| SCHEMBL16896257 | 0.69 | BTK (0.44) | NPY5RBTKRAB9AKDM4ELDHA | |
| SCHEMBL30404893 | 0.68 | NPY5R (0.51) | NPY5RBTKRAB9AKDM4ELDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | ABCG2, ATP5ME, DNTT | NPY5R 4855/4885BTK 2660/4885RAB9A 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.